perpetuity.

It is made available under a CC-BY-NC 4.0 International license.

- Glycaemic control and associated factors among patients living with type 2 diabetes in 2
- 3 Kinshasa, Democratic Republic of the Congo: a Cross-sectional study
- Jean-Pierre Fina Lubaki, 1,2 Olufemi Babatunde Omole, 1 Joel Msafiri Francis1 5
- Jean-Pierre Fina Lubaki, MMED, 7
- Department of Family Medicine and Primary Care, University of the Witwatersrand, 2050, 8
- 9 Johannesburg, South Africa

1

4

6

18

22

- Department of Family Medicine and Primary Care, Protestant University of the Congo, Kinshasa, 10
- Democratic Republic of the Congo 11
- **Olufemi Babatunde Omole** 12
- Department of Family Medicine and Primary Care, University of the Witwatersrand, 2050, 13
- Johannesburg, South Africa 14
- **Joel Msafiri Francis** 15
- Department of Family Medicine and Primary Care, University of the Witwatersrand, 2050, 16
- 17 Johannesburg, South Africa
- 19 *Corresponding author:
- Jean-Pierre Fina Lubaki, Email: 2136297@students.wits.ac.za email to: jeanpierrefina@yahoo.fr, 20
- Phone number: +243810703909 21

23 **Keywords:** Diabetes Mellitus, Type 2; Epidemiology; Disease Management; Developing

24 Countries

26

27

28

29

30

31

32

33

35

36

41

42

43

25 Word count: Abstract: 255, Main text: 3942

Number of tables: 4

SIGNIFICANCE OF THE STUDY

What is already known on this topic

- Glycaemic control is poor in most of the SSA settings, with glycaemic control ranging from 10–60%.
- Factors associated with glycaemic control are context specific; in the Democratic Republic
 of the Congo, few studies have investigated poor glycaemic control.

34 What this study adds

- The extent of poor glycaemic control among patients living with type 2 diabetes is determined in Kinshasa, Democratic Republic of the Congo.
- Identification of factors associated with poor glycaemic control in Kinshasa: taking only
 insulin and having a treatment duration ≥7 years increased the likelihood of poor
 glycaemic control, while being overweight and having uncontrolled blood pressure were
 protective.

How this study might affect research, practice or policy

 The study findings will inform potential interventions to improve glycaemic control in Kinshasa, DRC or similar settings elsewhere. 44 **ABSTRACT Objectives** 45 To assess the prevalence and factors associated with glycaemic control to inform potential 46 interventions to improve glycaemic control in Kinshasa, Democratic Republic of the Congo. 47 48 Design 49 This was a cross-sectional study conducted between November 2011–September 2022. We 50 conducted the selection of the participants through a two-stage sampling process. Participants were asked to complete a structured questionnaire and to provide two millilitres of blood for 51 Hb1AC assay. We performed univariate and multivariable logistic regressions to identify factors 52 associated with poor glycaemic control. 53 54 **Setting** 55 A total of 20 randomly selected primary care facilities in Kinshasa, Democratic Republic of the 56 Congo. **Participants** 57 The sample included 620 patients living with type 2 diabetes with a median age of 60 (IQR=53.5-58 69) years. 59 60 Results Most of the study participants were female (66.1%), unemployed (67.8%), having income below 61 the poverty line (76.4%), and without health insurance (92.1%). Two-thirds of the participants 62 (420; 67.6%) had poor glycaemic control. Those participants having taken only insulin (AOR=1.64, 63 95%CI 1.10 to 2.45) and those on a treatment duration ≥7 years (AOR=1.45, 95%CI 1.01 to 2.08) 64 were associated with increased odds of poor glycaemic control, while being overweight (AOR= 65

0.47, 95%CI 0.26 to 0.85) and those with uncontrolled blood pressure (AOR=0.65, 95% CI 0.48 to
 0.90) were protective for poor glycaemic control.
 Conclusions
 This study confirms that poor glycaemic control is common among patients living with type 2
 diabetes in Kinshasa, DRC. There is a need for targeted interventions to improve glycaemic
 control, including metabolic and clinical comorbidity control, lifestyle modifications, and health
 system factors.

74

INTRDODUCTION

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

Type 2 diabetes is increasing worldwide¹ – it is expected that the greatest increase in diabetes prevalence will take place in low- and middle-income countries between 2021 to 2045.² On the African Continent, type 2 diabetes is progressing rapidly due to modifiable risk factors, such as obesity and urbanisation.² In sub-Saharan Africa (SSA), diabetes care faces numerous challenges leading to unmet needs and a greater impact on morbidity and mortality.^{3 4} In the Democratic Republic of the Congo (DRC), the prevalence of diabetes is estimated to be 5.8% for adults aged 20 to 79 years, 4 with a high proportion of persons living with diabetes in urban areas and the western part of the country. ^{5 6} The factors associated with diabetes were being male, aged ≥ 40 years, general and abdominal obesity associated with the elderly, family history of diabetes, and hypertension.6 Glycaemic control is the cornerstone of diabetes management, as it delays the occurrence of complications, reduces the cost of care and improves patient quality of life. Nevertheless, the control of diabetes remains a worldwide issue, with only about 50% of the patients living with type 2 diabetes controlled. In SSA, it is estimated that only one-third of patients living with type 2 diabetes reached target glycaemic levels. 89 The accurate knowledge of factors driving glycaemic control in a particular setting is essential to build up an intervention package to improve glycaemic control. Multiple factors drive glycaemic control in SSA, differing across settings.8 A recent systematic review of the studies on glycaemic control found: younger and older age, gender, poor socio-economic conditions, place of living, positive family history of diabetes, longer duration of diabetes, treatment modalities and effects, alcohol consumption, smoking presence of comorbidities or complications, and poor management were associated with poor glycaemic

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

control.⁹ Contrarily, high diabetes health literacy, positive perceived family support, adequate coping strategies, dietary adherence, exercise practice, attendance of follow-up appointments, and medication adherence were associated with good glycaemic control.9 In the DRC, very few studies have investigated poor glycaemic control among persons/patients living with type 2 diabetes, as high as 86% in the nearby province of Kwilu¹⁰ and 79.9% in Kinshasa.¹¹ Only a few reported factors were found to be associated with glycaemic control among persons living with type 2 diabetes mellitus in the DRC. Sagastume et al 11 found older patients (> 40 years) had increased odds of achieving glycaemic control than younger patients (< 40 years), while Blum et al 10 noticed that abdominal obesity and having a body mass index (BMI) > 25 Kg/m2 have been associated with poor glycaemic control. Moreover, we noticed that no study in our setting had previously assessed the link between psychological factors and poor glycaemic control. This study aimed to assess the extent of glycaemic control and to broaden the knowledge on factors driving poor glycaemic control among patients living with type 2 diabetes in Kinshasa. The results will serve to build an intervention package to improve glycaemic control among patients living with type 2 diabetes in Kinshasa. **METHODS** This study is a component of the research project on glycaemic control among patients living with type 2 diabetes in Kinshasa, DRC, for which the study protocol was previously published. 12 **Ethics**

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

The researchers declared that they complied with the conditions under which this study obtained approval from the ethics committees of the Protestant University of Congo (reference number: CEUPC 0067; Date: 05/02/2021) and Human Research Ethics Committee (Medical) of the University of the Witwatersrand (reference number: M210308; Date: 26/08/2021). The study was conducted according to the ethical guidelines of the Declaration of Helsinki. Permission was obtained from the Kinshasa Primary HealthCare Network to conduct the study. Informed consent was obtained from each participant. Data collection was done with strict adherence to local COVID-19 regulations. Type of study This was a cross-sectional study among patients recruited from 20 randomly selected health facilities in Kinshasa, DRC. **Study setting** Our study was multisite within the city of Kinshasa, the DRC's capital, with an estimated total population of about 15 million inhabitants spread over an area of 9,965 km². ¹³ The study was conducted in the health facilities belonging to the Catholic Church and the Salvation Army. With a total of 66 health facilities (1 referral hospital and 65 health centres) distributed across 24 health districts, these organisations own most of the facilities that have integrated diabetes care in primary care. Study population The study population consisted of patients living with type 2 diabetes attending health centres offering diabetes care in the Kinshasa Primary Care Network, with about 7326 patients registered in 2020. The inclusion criteria were age ≥18 years and receiving diabetes treatment for at least six months. The exclusion criteria were pregnancy, difficulty communicating due to mental disability, and refusal to provide consent for the study.

Sample size estimation

The estimated minimum sample size was computed using Epi info version 7.2.2.2. Assuming that the prevalence of poor glycaemic control was 68%,¹⁴ with a 95% confidence level and a power of 80%, some 59,2% of patients who had a diabetes duration ≤7 years (unexposed) presented with poor glycaemic control, and 74,4% of those who had a diabetes duration >7 years (exposed) presented with poor glycaemic control. The unexposed to exposed ratio is 0.47.¹⁵ The minimum estimated sample size was 368. Adjusting for a design effect of 1.5, the calculated sample size of 552 was determined. To account for an estimated 10% non-response rate, the minimum required sample size was 614 patients, rounded up to 620 patients.

Sampling of participants

The selection of the participants was conducted using a two-stage sampling process. The first stage was the selection of healthcare facilities. As the healthcare facilities have an unequal number of patients, the participants were selected by probability proportional to the patient population size. Using this strategy, we randomly selected 20 healthcare facilities out of a possible 48. In the second stage, a minimum of 31 patients were selected from each selected healthcare facility using systematic sampling. This process ensured each patient had the same overall probability of selection or self-weighting. The sampling was done without replacement.

Data collection

The data collection process lasted from November 2021–September 2022. For each participant, the research team performed physical and anthropometric measurements. These measurements

were taken once by trained staff members on the same portable equipment at all the health facilities. The questionnaires were pre-existing standardised questionnaires translated from English into French and Lingala. The questionnaires were tested before data collection and validated for use. At the end of the data collection, a blood sample was taken from the participant. The questionnaire was administered on a tablet or smartphone using REDCap (Research Electronic Data Capture). The information about the diabetes disease was verified with information in the patient's medical records, if available.

Variables of the study

Outcome

The main outcome variable was poor glycaemic control which was defined as HbA1c ≥7%,¹⁷ which was assayed at the laboratory of the School of Medicine at the Protestant University of Congo in Kinshasa. The analysis was completed using an automated Genuis WP 21B with antibody-based immunoassay method of Cypress Diagnostics.¹⁸

Exposures

The possible determinants for glycaemic control sought from the participants were sociodemographic parameters (age, sex, marital status, religion, education level, occupation, ethnic group, income, health insurance, access to food, distance from place of residence to health centre), lifestyle parameters (smoking, risky drinking), clinical parameters (duration of diabetes, height, weight, body mass index, waist circumference, presence of comorbidities, blood pressure, treatment, duration of treatment), and psychological parameters (adherence to treatment,

depression, diabetes distress, social support, self-management, knowledge). Supplementary file 1 detailed the exposures, their measurements, operational definitions, reliability, and references.

Data analysis

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

All the analyses were performed using survey data analysis with STATA 17 to account for the study design characteristics. We expressed age as median with interquartile range (IQR), as it was not normally distributed. The other variables were analysed as categorical variables and expressed as frequency (n) and percentage (%). Bivariate analysis was performed to compare uncontrolled versus controlled participants in terms of glycosylated haemoglobin using the Chisquare test/Fisher exact test for categorical variables. We further carried out multivariable logistic regression to assess factors associated with glycaemic control. Age, sex, duration of treatment, and food security were included in the regression model a priori. Other variables with a p-value <0.2 in univariate analysis were also included in the model. The p-value of <0.05 was considered statistically significant.

RESULTS

A total of 620 participants were included in the study out of a total of 627 invited, accounting for a non-response rate of 1.1%. Table 1 summarises the sociodemographic characteristics of the participants.

Table 1 Sociodemographic chadiabetes, Kinshasa, n=620, 202	aracteristics of the patients living with type 2 21-2022
	N (%)
Age	
18-39	39 (6.4)
40-64	342 (55.1)
≥ 65	239 (38.5)

Cov	
Sex	214 /22 0\
Male	211 (33.9)
Female	409 (66.1)
Marital status	100 (22.2)
Single	199 (32.2)
Married	393 (63.3)
Other	28 (4.5)
Ethnic group	
Kongo	502 (80.9)
Luba	30 (5.0)
Ngala	36 (5.9)
Swahili	19 (3.1)
Other	32 (5.2)
Religion	
Catholic	281 (45.4)
Protestant	128 (20.6)
Independent	167 (26.9)
Other	44 (7.1)
Educational level	
No formal education	77 (12.5)
Primary school	199 (32.1)
Secondary school	269 (43.4)
University	75 (12.1)
Occupation	,
Employed	132 (21.1)
Unemployed	419 (67.7)
Other	69 (11.2)
Income	,
Below the poverty line	473 (76.4)
Above the poverty line	147 (23.6)
Access to food	(/
Food secure	249 (40.0)
Mildly Food Insecure Access	77 (12.5)
Moderately Food Insecure	107 (17.3)
Access	107 (17.0)
Severely Food Insecure Access	187 (30.2)
Health insurance	107 (00.2)
Insured	49(7.9)
Without health insurance	571 (92.1)
Distance to a health facility	3/1 (32.1)
•	451 (72.6)
Nearby	· · · · · · · · · · · · · · · · · · ·
Distant	165 (27.4)

Prevalence of glycaemic control and participants' characteristics

About two-thirds of the participants (67.8%; n=420) had poor glycaemic control. There was no statistically significant difference between controlled and uncontrolled participants in terms of sociodemographic characteristics (Table 2).

Table 2 Sociodemographic characteristics and glycaemic control among patients living with type 2 diabetes in Kinshasa, Democratic Republic of the Congo, n=620, 2021-2022

	Controlled	Uncontrolled	All participants	р
	(n, %(95%CI))	(n, %(95%CI))	(n, %)	
Age				0.479
18-39	9 (22.8 (10.7 to 42.2))	30 (77.2 (57.8 to 89.3))	39 (100.0)	
40-64	112 (32.7 (26.7 to 39.4))	230 (67.3 (60.6 to 73.3))	342 (100.0)	
≥ 65	79 (33.0 (24.8 to 42.2))	160 (67.0 (57.6 to 75.2))	239 (100.0)	
Sex				0.989
Male	68 (32.2 (24.6 to 40.8))	143 (67.8 (59.2 to 75.4))	211 (100.0)	
Female	132 (32.2 (25.3 to 40.0))	277 (67.8 (60.0 to 74.7))	409 (100.0)	
Marital status				0.413
Single	68 (34.3 (25.7 to 43.9))	131 (65.7 (56.1 to 74.3))	199 (100.0)	
Married	126 (31.3 (25.4 to 39.3))	267 (65.7 (60.7 to 74.6))	393 (100.0)	
Other	6 (21.3 (9.7 to 40.6))	22 (78.7 (59.4 to 90.3))	28 (100.0)	
Ethnic group				0.405
Kongo	156 (31.0 (24.9 to 37.9))	346 (69.0 (62.1 to 75.1))	502 (100.0)	
Luba	13 (42.0 (25.5 to 60.4))	18 (58.0 (39.6 to 74.5))	31 (100.0)	
Ngala	14 (38.7 (26.2 to 52.9))	22 (61.3 (47.1 to 73.8))	36 (100.0)	
Swahili	8 (42.0 (24.4 to 61.8))	11 (58.0 (38.2 to 75.6))	19 (100.0)	
Other	8 (28.1 (13.5 to 49.5))	23 (71.9 (50.5 to 86.5))	32 (100.0)	
Religion				0.201
Catholic	92 (32.7 (25.7 to 40.7))	189 (67.3 (59.3 to 74.3))	281 (100.0)	
Protestant	44 (34.3 (25.4 to 44.6))	84 (65.7 (55.4 to 74.6))	128 (100.0)	
Independent	44 (26.2 (16.7 to 38.6))	123 (73.8 (61.4 to 83.3))	167 (100.0)	
Other	20 (45.3 (30.5 to 60.9))	24 (54.7 (39.1 to 69.5))	44 (100.0)	
Educational status				0.781
No formal	28 (36.4 (18.2 to 59.7))	49 (63.6 (40.3 to 81.8))	77 (100.0)	
Primary school	64 (32.1 (24.6 to 40.6))	135 (67.9 (59.4 to75.4))	199 (100.0)	
Secondary school	87 (32.3 (25.9 to 39.4))	182 (67.7 (60.6 to 74.1))	269 (100.0)	

University	21 (27.9 (19.5 to 38.3))	54 (72.1 (61.7 to 80.5))	75 (100.0)	
Occupation				0.518
Employed	45 (34.1 (27.2 to 41.9))	87 (65.9 (58.1 to 72.8))	132 (100.0)	
Unemployed	130 (30.9 (24.1 to 38.8))	289 (69.1(61.2 to 75.9))	419 (100.0)	
Other	25 (36.3 (25.6 to 48.6))	44 (63.7 (51.4 to 74.4))	69 (100.0)	
Income				0.342
Below the poverty line	149 (31.4 (25.1 to 38.5))	324 (68.6 (61.5 to 74.9))	473 (100.0)	
Above the poverty line	51 (34.7 (27.8 to 42.4))	96 (65.3 (57.6 to 72.2))	147 (100.0)	
Access to food				0.192
Food secure	69 (27.6 (19.7 to 37.3))	180 (72.4 (62.7 to 80.3))	249 (100.0)	
Mildly Food Insecure	28 (36.5 (24.2 to 50.9))	49 (63.5 (49.1 to 75.8))	71 (100.0)	
Moderately Food Insecure	43 (40.2 (31.5 to 49.6))	64 (59.8 (50.4 to 68.5))	107 (100.0)	
Severely Food Insecure	60 (31.9 (24.0 to 41.1))	127 (68.1 (58.9 to 76.0))	187 (100.0)	
Health insurance				0.782
Insured	17 (34.5 (20.2 to 52.2))	32 (65.5 (47.8 to 79.8))	48 (100.0)	
Uninsured	183 (32.0 (25.8 to 39.0))	388 (68.0 (61.0 to 74.2))	571 (100.0)	
Distance to a health facility				0.644
Nearby	148 (32.8 (25.8 to 40.6))	303 (67.2 (59.4 to 74.2))	451(100.0)	
Distant	52 (30.7 (23.7 to 38.7))	117(69.3 (61.3 to 76.3))	169 (100.0)	

However, controlled participants differed significantly from uncontrolled participants in terms of BMI (p=0.005), control of blood pressure (p=0.027), and treatment regimens (p=0.002) (Table 3).

Table 3 Lifestyle and clinical characteristics and glycaemic control among patients living with type 2 diabetes in Kinshasa, Democratic Republic of the Congo, n=620, 2021-2022

	Controlled	Uncontrolled	All participants	р
	(n, %(95%CI))	(n, %(95%CI))	(n, %)	
Smoking				0.268
No	200 (32.4 (26.5 to 38.9))	416 (67.6 (61.1 to 73.5))	616 (100.0)	
Yes	0 (0.0 (0.0))	4 (100.0 (0.0))	4 (100.0)	
Alcohol disorder				0.566
No disorder	198 (32.4 (26.5 to 38.8))	413 (67.6 (61.2 to 73.5))	611 (100.0)	
Health risk consumption	2 (22.1 (4.0 to 66.2))	7 (77.9 (33.8 to 96.0))	9 (100.0)	
Duration of diabetes				0.549
0-5 years	84 (31.3 (23.0 to 41.0))	183 (68.7 (59.0 to 77.0))	267 (100.0)	
5-10 years	76 (35.1 (26.5 to 44.8))	141 (64.9 (55.2 to 73.5))	217 (100.0)	
≥10 years	40 (29.3 (22.2 to 37.5))	96 (70.7 (62.5 to 77.8))	136 (100.0)	
Body mass index				0.005*
Underweight	14 (21.6 (13.4 to 33.0))	51 (78.4 (67.0 to 86.6))	65 (100.0)	
Normal	102 (29.3 (21.9 to 37.9))	245 (70.7 (62.1 to 78.1))	347 (100.0)	
Overweight	66 (46.6 (39.1 to 54.2))	76 (53.4 (45.8 to 60.9))	142 (100.0)	
Obesity	18 (27.3 (15.7 to 43.1))	48 (72.7 (56.9 to 84.3))	66 (100.0)	
Waist circumference				0.083
Abnormal	93 (38.2 (29.8 to 47.3))	150 (61.8 (52.7 to 70.2))	243 (100.0)	
Normal	107 (28.3 (21.5 to 36.3))	270 (71.7 (63.7 to 78.5))	377 (100.0)	
Presence of comorbidities				0.266
Yes	136 (33.9 (27.6 to 40.7))	265 (66.1 (59.3 to 72.4))	401 (100.0)	
No	64 (29.2 (21.6 to 38.1))	155 (70.8 (61.9 to 78.4))	218 (100.0)	
Blood pressure				0.027*
Controlled	117 (29.2 (22.9 to 36.4))	283 (70.8 (63.6 to 77.1))	400 (100.0)	

Uncontrolled	83 (37.7 (30.8 to 45.2))	137 (62.3 (54.8 to 69.2))	220 (100.0)	
Treatment				0.002*
Insulin	87 (26.0 (20.7 to 32.1))	247 (74.0 (67.9 to 79.3))	334 (100.0)	
Oral hypoglycaemic drugs	98 (41.3 (31.6 to 51.7))	139 (58.7 (48.3 to 68.4))	237 (100.0)	
Mixed	15 (30.7 (21.1 to 42.3))	34 (69.3 (57.7 to 78.9))	49 (100.0)	
Duration of treatment				0.229
< 7 years	132 (34.1 (27.3 to 41.6))	255 (65.9 (58.4 to 72.7))	387 (100.0)	
≥ 7 years	68 (29.1 (21.9 to 37.4))	165 (70.9 (62.6 to 78.1))	233 (100.0)	
* 40 05				

238 *p<0.05

Perceived support from significant others (p=0.005), perceived family support (p=0.020), diabetes treatment regimen distress (p=0.029), and adherence to physical activity (p=0.017) were statistically significant between controlled and uncontrolled participants (Supplementary table 1). **Determinants of glycaemic control** Being on insulin (AOR=1.64, 95%CI 1.10 to 2.45) and having a treatment duration ≥7 years (AOR=1.45, 95%CI 1.01 to 2.08) were associated with increased odds of poor glycaemic control. Being overweight (AOR= 0.47, 95%CI 0.26 to 0.85) and having uncontrolled blood pressure (AOR=0.65, 95% CI 0.48 to 0.91) were associated with decreased odds of poor glycaemic control (Table 4).

Table 4 Results of survey logistic regression estimating the association between different exposures and poor glycaemic control in 620 patients with type 2 diabetes in Kinshasa, Democratic Republic of the Congo, 2021-2022

	Univariate analysis		Multivariate analysis	
	р	COR (95%CI)	р	AOR (95%CI)
Age (years)				
18-39		1		1
40-64	0.276	0.61 (0.24 to 1.54)	0.652	0.81 (0.32 to 2.08)
≥ 65	0.271	0.60 (0.23 to 1.54)	0.736	0.86 (0.35 to 2.13)
Sex				
Male		1		1
Female	0.989	1.00 (0.64 to 1.55)	0.494	1.16 (0.75 to 1.79)
Access to food		·		
Food secure		1		1
Mildly Food Insecure	0.199	0.66 (0.35 to 1.27)	0.079	0.59 (0.33 to 1.07)
Moderately Food Insecure	0.008	0.57 (0.38 to 0.85)	0.083	0.69 (0.46 to 1.05)
Severely Food Insecure 0.468		0.81 (0.45 to 1.46)	0.670	0.90 (0.53 to 1.51)
Body mass index				
Underweight		1		1
Normal	0.178	0.66 (0.36 to 1.22)	0.288	0.73 (0.41 to 1.32)
Overweight	0.000	0.32 (0.18 to 0.55)	0.015*	0.47 (0.26 to 0.85)
Obese	0.515	0.73 (0.28 to 1.94)	0.574	1.21 (0.60 to 2.48)
Waist circumference				
Normal		1		1
Abnormal	0.084	0.64 (0.38 to 1.07)	0.328	0.80 (0.51 to 1.26)
Blood pressure				
Controlled		1		
Uncontrolled	0.027	0.68 (0.84 to 0.95)	0.011*	0.65 (0.48 to 0.90)
Duration of treatment (years)				
< 7		1		1

≥7	0.229	1.26 (0.85 to 1.87)	0.043*	1.45 (1.01 to 2.08)
Treatment regimen				
OAD		1		1
Insulin	0.003	2.00 (1.31 to 3.05)	0.019*	1.10 (1.10 to 2.45)
Mixed	0.144	1.59 (0.84 to 2.99)	0.319	1.39 (0.71 to 2.74)
Significant other support				
Low support		1		1
Moderate support	0.465	0.85 (0.54 to 1.34)	0.244	0.78 (0.51 to 1.20)
High support	0.002	0.42 (0.25 to 0.71)	0.128	0.64 (0.36 to 1.15)
Family support				
Low support		1		1
Moderate support	0.586	1.14 (0.69 to 1.91)	0.533	1.22 (0.63 to 2.34)
High support	0.015	0.50 (0.29 to 0.86)	0.359	0.70 (0.31 to 1.55)
Diabetes distress				
No distress		1		1
Moderate distress	0.017	1.75 (1.12 to 2.73)	0.179	1.42 (0.84 to 2.39)
High distress	0.009	1.72 (0.83 to 3.54)	0.901	0.95 (0.42 to 2.23)
Physical activity				
Poor adherence		1		1
Good adherence	0.019	1.55 (1.08 to 2.22)	0.067	1.34 (0.98 to 1.80)
Knowledge on diabetes				
Low		1		1
Acceptable	0.004	1.45 (1.14 to 1.83)	0.054	0.69 (0.48 to 1.01)
Good	0.846	1.04 (0.68 to 1.59)	0.419	1.13 (0.83 to 1.52)
*n<0.05		· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·

267 *p<0.05

DISCUSSION

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

This study was designed to assess the extent of poor glycaemic control among patients living with type 2 diabetes in Kinshasa, including its driving factors. The results found a prevalence of poor glycaemic control of 67.8%. No sociodemographic and lifestyle characteristics were associated with glycaemic control. Taking only insulin and having a treatment duration ≥7 years increased the odds of poor glycaemic control, while being overweight and having uncontrolled blood pressure were protective. This study found that more than two-thirds of the participants have poor glycaemic control, thus corroborating the findings of other studies in SSA. 89 Furthermore, this study found a higher prevalence of poor glycaemic control than that found by Blum et al in the nearby rural province of Kwilu in the DRC. Findings from this study are lower than those found in the European or North American studies, ^{19 20} and indicated poor diabetes care in Kinshasa. These results also translated the issues in SSA in general, where diabetes care faces multiple barriers. 321 Moreover, self-management in SSA is poor and represents a threat to the health of individuals and capacity of the health system.²² Meanwhile, diabetes is becoming more predominant, with great economic and health impacts. 3 21 In a study in the Kinshasa Health Network in 2015, Kapongo et al found that the capacities, knowledge, and practice of type 2 diabetes care were poor and stated that the training of healthcare professionals, equipment of health facilities and development of clinical guidelines could help in improving glycaemic control.²³ Thus, effective funding, and better preparation for diabetes care is crucial.

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

Most of our participants (93.7%) were older than 40 years. This proportion aligns with the classic description of type 2 diabetic patients, in which the disease appears in individuals older than 40 years most of the time. Female patients represented approximately two-thirds of the participants. A retrospective analysis of the Kinshasa Health Network database conducted by Sagastume et al¹¹ also found the same-sex prevalence. This high prevalence of type 2 diabetes affects more women than men, due to the higher metabolic risk in the former.²⁴ Furthermore, the health-seeking behaviour of women is greater than men.²⁵ A distribution of religion and ethnic groups among the participants corresponded linearly to the distributions of those parameters in the general population. Most of the participants were unemployed, poor and without health insurance, which has been representative of the condition of the general population in Kinshasa. No sociodemographic and lifestyle characteristics were associated with poor glycaemic control. Our finding here has been corroborated by the study of Blum et al, 10 who also found no sociodemographic or lifestyle factors associated with poor glycaemic control in a cross-sectional survey in the nearby province of Bandundu in the DRC. We suppose that the tools used to characterise patients were unsuitable for the particularities of our setting. A recent systematic review on glycaemic control among patients living with type 2 diabetes in SSA found that younger and older age, gender, lower income, absence of health insurance, low level of education, and place of residence were associated with poor glycaemic control.9 In a retrospective study in Kinshasa, Sagastume et al¹¹ found that younger patients needed prioritised attention to reach glycaemic targets. Research with more appropriate and suitable tools will be needed to better define the contribution of sociodemographic and lifestyle characteristics on glycaemic control in our setting. Nevertheless, interventions for better glycaemic control have to

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

prioritise vulnerable groups, such as younger and older age, women and non-insured patients. Implementing universal coverage can increase access to care for the aforementioned groups.²⁶ In this study, participants taking only insulin were 1,64 times more likely to have poor glycaemic control than those on oral hypoglycaemic drugs. Studies have shown that only around one-fourth of patients on insulin could achieve glycaemic targets because the participants might be erroneously taking an insufficient daily dose and incorrectly titrating insulin.²⁷ The lack of adherence to the prescribed regimen has been also a significant factor in poor glycaemic control and was magnified in our setting, as most of the patients were unemployed and not covered by health insurance. They were unable to adequately follow the prescribed regimen when they lacked food. The psychological resistance to insulin, prevalent in our setting according to the study by Rita et al, 28 could also be another explanation for poor glycaemic control among patients living with type 2 diabetes in our study. In the diabetes attitudes, wishes and needs second study (DAWN), participants reported low confidence in the efficacy of insulin, with 26.9% of participants abstaining from insulin because they thought insulin unfeasible or impracticable to manage their diabetes.²⁹ Healthcare providers must ensure that psychological resistance to initiating insulin is adequately addressed, and effectively train the patients to correctly follow their prescriptions. Type 2 diabetes is a lifestyle disease, and all guidelines prescribe that insulin therapy should be accompanied by lifestyle modification and oral hypoglycaemic drugs. The prepotency of insulin use highlighted the lack of appropriate guidelines or poor clinicians' adherence to evidence-based clinical guidelines. Clear management guidelines must also be adapted for the use of available medicines and efforts must be made to offer new hypoglycaemic agents at affordable prices.

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

In this study, the odds of overweight participants having poor glycaemic control were reduced by 53.0%. Blum et al10, in their study near Kinshasa, also found that BMI>25 Kg and abdominal obesity were protective against poor glycaemic control. The authors stated that this finding could reflect the existence of special features of diabetes in SSA. Plečko et al,30 in an analysis encompassing four large international clinical databases for critically ill patients, found that higher BMI in patients with diabetes was associated with lower average glucose. The authors suggested that their finding could be explained by the process of care, as the patients with higher BMIs had more glucose measurements and were receiving higher insulin doses. Our finding contrasted the well-known relationship between being overweight and suboptimal glycaemic control and poor glycaemic control.³¹ Weight loss or the prevention of weight gain is an important goal in the management of type 2 diabetes or prediabetes.³² However, increasing weight could also arise in diabetic patients due to the effect of antidiabetic medication on body weight. Apart from metformin and thiazolidinediones, other antidiabetic agents could lead to weight gain. 33 In Kinshasa, insulin is largely used and there has been a limited range of affordable medications for patients. Healthcare providers must furthermore ensure that the patients are adequately managed to avoid adverse effects.³³ In the study sample, patients with uncontrolled blood pressure reduced the odds of having poor glycaemic control by 35.0%. Mobula et al,34 in a Ghanaian study, also found that systolic blood pressure was significantly higher among patients with adequate glycaemic control compared to the group with poor glycaemic control. As discussed by Mobula et al,34 among patients with good glycaemic control, it can be that there was a significantly higher proportion of patients with dual diagnosis—hypertension and diabetes. This observation can also be explained by the fact that health providers give more attention to persons with comorbidity or an increase in healthcare utilisation by the persons with comorbidity.³⁵ Hypertension is frequently associated with diabetes,³⁶ which indicates that more insight into adequate management of hypertension among patients with diabetes in our setting will be required.³⁵

This study found that a treatment duration ≥7 years increased the odds of poor glycaemic control by 1,45 times. Longer duration of treatment has been linked to poor glycaemic control in SSA.³⁷
As diabetes takes longer to emerge, there is a progressive deterioration of the pancreas function, therefore requiring more adjustments in the treatment of older patients, who can develop comorbidities.³⁸ One may note that in SSA, there has been a high proportion of undiagnosed diabetes, and usually at the time of diagnosis made the disease is relatively advanced with complications already present.³⁹ Health providers must be informed of the progression of diabetes and be able to adjust the treatments for patients accordingly.

Limitations of the study

This study estimated the extent of poor glycaemic control among type 2 diabetes patients in Kinshasa. Also, we have broadly assessed psychological scales regarding glycaemic control in SSA to promote understanding in the management of patients with diabetes. Because of the cross-sectional nature of the study, it is not possible to ascertain a causal relationship between poor glycaemic control and the determinants. Other potential biases include selection (non-response of the eligible participants), recall, interviewer, and social desirability. These biases were minimised by ensuring effective training of the data collectors to make certain that the aim and objectives of the study were clearly stated to the participants, and that questions asked were communicated with a non-judgemental attitude.

perpetuity.

It is made available under a CC-BY-NC 4.0 International license .

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

CONCLUSION This study confirms that poor glycaemic control is common among patients living with type 2 diabetes in Kinshasa, DRC. There is a need for targeted interventions to improve glycaemic control, including metabolic and clinical comorbidity control, lifestyle modifications, and health system factors. Special acknowledgement The authors would like to thank all the staff of the Kinshasa Primary Health Network for their support during the study. We thank Mrs Manase Lusuami for performing the laboratory assays, and Christian Mungongo Kifu for his support during data collection and data management. **Author Contributions** JPF (guarantor), OBO, and JMF designed the study. JPF contributed to acquisition of funding and data. JPF oversaw the research process. JPF and JMF performed the data processing and quality control. JPF conducted the statistical analyses, drafted the manuscript, and is the guarantor of this work. JPF, OBO, and JMF interpreted the data. All authors edited and critically reviewed the manuscript for intellectual content and approved the final version. **Funding support** The authors received no specific funding for this work. The Protestant University of Congo provided laboratory reagents and facilitated laboratory assays. **Declaration of interests**

The authors declare that they have no competing interests.

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

5.

Patient consent for publication Informed consent was obtained from each participant. Data availability statement All datasets supporting the conclusions in this article are included within the article. **Disclaimers** The authors stated that the views expressed in this article are their own and not an official position of the institution or funder. **REFERENCES** 1. Internation Diabetes Federation, IDF Diabetes Atlas Ninth, Dunia: IDF, 2019. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level 2. diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022 Jan 1;183:109119. 3. Pastakia S, Pekny C, Manyara S, et al. Diabetes in sub-Saharan Africa – from policy to practice to progress: targeting the existing gaps for future care for diabetes. Diabetes, Metab Syndr Obes Targets Ther 2017 Jun;10:247–63. http://www.ncbi.nlm.nih.gov/pubmed/28790858 (Accessed 10 Nov 2019) 4. Democratic Republic of the Congo diabetes report 2000 — 2045. https://diabetesatlas.org/data/en/country/55/cd.html (Accessed 21 Dec 2022)

Katchunga PB, Mirindi P, Baleke A, et al. The trend in blood pressure and hypertension

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

prevalence in the general population of South Kivu between 2012 and 2016: Results from two representative cross-sectional surveys-The Bukavu observational study. PLoS One 2019;14(8):e0219377. 6. Muyer MTMC, Botomba S, Poka N, et al. Diabetes prevalence and risk factors, underestimated without oral glucose tolerance test, in rural Gombe-Matadi Adults, Democratic Republic of Congo, 2019. Sci Rep 2022 Dec;12(1):15293. /pmc/articles/PMC9467973/ (Accessed 21 Dec 2022) 7. Giugliano D, Maiorino MI, Bellastella G, et al. Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine 2018 Jul 1;61(1):23-7. 8. Sobngwi E, Ndour-Mbaye M, Boateng KA, et al. Type 2 diabetes control and complications in specialised diabetes care centres of six sub-Saharan African countries: The Diabcare Africa study. Diabetes Res Clin Pract 2012 Jan;95(1):30–6. http://dx.doi.org/10.1016/j.diabres.2011.10.018 (Accessed 26 Apr 2020) Lubaki F, Omole OB, Francis JM. Glycaemic control among type 2 diabetes patients in sub 9. - Saharan Africa from 2012 to 2022 : a systematic review and meta - analysis. Diabetology & Metabolic Syndrome 2022: 1-78 https://doi.org/10.1186/s13098-022-00902-0 (Accessed 21 Dec 2022) 10. Blum J, Chaney M, Mudji J, et al. Glycaemic control among patients with type 2 diabetes followed in a rural African primary care setting - A reality check in the Democratic Republic of Congo. Prim Care Diabetes. 2020;14(2):139-46.

Sagastume D, Mertens E, Sibongwere DK, et al. A retrospective database study of the 438 11. demographic features and glycemic control of patients with type 2 diabetes in Kinshasa, 439 Democratic Republic of the Congo. BMC Med 2022;20(1):1–14. 440 https://doi.org/10.1186/s12916-022-02458-2 (Accessed 21 Dec 2022) 441 Fina Lubaki JP, Omole OB, Francis JM. Protocol: Developing a framework to improve 12. 442 glycaemic control among patients with type 2 diabetes mellitus in Kinshasa, Democratic 443 444 Republic of the Congo. PLoS One 2022;17(9):e0268177. http://dx.doi.org/10.1371/journal.pone.0268177 (Accessed 21 Dec 2022) 445 13. Megacity Kinshasa Eyes Climate Resilient Future Through Urban Management. 446 https://www.worldbank.org/en/news/feature/2021/08/19/why-kinshasa-could-be-in-447 the-vanguard-of-megacities-climate-resilience (Accessed 2 Mar 2022) 448 Longo-Mbenza B, Kasiam Lasi On'kin JB, Nge Okwe A, et al. The metabolic syndrome in a 14. 449 Congolese population and its implications for metabolic syndrome definitions. Diabetes 450 Metab Syndr 2011;5(1):17-24. 451 452 15. Chetoui A, Kaoutar K, Elmoussaoui S, et al. Prevalence and determinants of poor glycaemic control: a cross-sectional study among Moroccan type 2 diabetes patients. Int 453 454 Health 2020;1–8. 455 16. REDCap. https://redcap.core.wits.ac.za/redcap/ (Accessed 4 Nov 2022) 17. Ministry of Public Health of the Democratic Republic of the Congo. [Standards and 456 guidelines for diabetes management]. 457

1]. https://extranet.who.int/ncdccs/Data/COD_B6_NV_Draft%20final_Normes%20Diab% 458 C3%A8te (Accessed 21 May 2021) 459 Cypress Diagnostics. HbA1c Turbi. https://diagnostics.be/fr/product/ht001 (Accessed 21 460 18. Dec 2022). 461 De Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and 462 19. its associated factors in patients with type 2 diabetes across Europe: Data from the 463 464 PANORAMA study. Clin Endocrinol (Oxf) 2014;80(1):47-56. 20. Fang M, Wang D, Coresh J, et al. Trends in Diabetes Treatment and Control in U.S. Adults, 465 466 1999–2018. N Engl J Med 2021 Jun 10;384(23):2219–28. 467 21. Motala AA, Mbanya JC, Ramaiya K, Pirie FJ, Ekoru K. Type 2 diabetes mellitus in sub-Saharan Africa: challenges and opportunities. Nat Rev Endocrinol 2022 Jan; 18(4):219–29. 468 https://www.nature.com/articles/s41574-021-00613-y (Accessed 21 Dec 2022) 469 470 22. Stephani V, Opoku D, Beran D. Self-management of diabetes in Sub-Saharan Africa: A 471 systematic review. BMC Public Health 2018. p. 1148. Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-018-6050-0 472 (Accessed 19 Apr 2020) 473 474 23. Kapongo RY, Lulebo AM, Mafuta EM, et al. Assessment of health service delivery capacities, health providers' knowledge and practices related to type 2 diabetes care in 475 Kinshasa primary healthcare network facilities, Democratic Republic of the Congo Health 476 services research in low and middle inco. BMC Health Serv Res 2015;15(1):1–6. 477

Goedecke JH, Olsson T. Pathogenesis of type 2 diabetes risk in black Africans: a South 478 24. African perspective. J Intern Med 2020;288(3):284-94. 479 25. Yeatman S, Chamberlin S, Dovel K. Women's (health) work: A population-based, cross-480 sectional study of gender differences in time spent seeking health care in Malawi. PLoS 481 One 2018;13(12):3-4. 482 Jackson Y, Lozano Becerra JC, Carpentier M. Quality of diabetes care and health 26. 483 484 insurance coverage: a retrospective study in an outpatient academic public hospital in Switzerland. BMC Health Serv Res 2016 Oct;16(1):1-7. 485 https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-016-1801-z 486 487 (Accessed 20 Dec 2021) Sendekie AK, Belachew EA, Dagnew EM, et al. Rate of glycaemic control and associated 488 27. factors in patients with type 2 diabetes mellitus treated with insulin-based therapy at 489 selected hospitals in Northwest Ethiopia: a multicentre cross-sectional study. BMJ Open 490 2022;12:65250. http://bmjopen.bmj.com/ (Accessed 20 Dec 2021) 491 492 28. Rita SL, Lubaki FJP, Bompeka LF, et al. Prevalence and determinants of psychological insulin resistance among type 2 diabetic patients in Kinshasa, Democratic Republic of 493 494 Congo. African J Prim Heal Care Fam Med 2019;11(1):1–5. 495 29. Funnell MM, Bootle S, Stuckey HL. The diabetes attitudes, wishes and needs second study. Clin Diabetes 2015;33(1):32-6. 496

Plečko D, Bennett N, Mårtensson J, et al. The obesity paradox and hypoglycemia in

497

30.

perpetuity.	
It is made available under a CC-BY-NC 4.0 International licer	nse .

498		critically ill patients. Crit Care 2021;25(1):1–15. https://doi.org/10.1186/s13054-021-
499		03795-z (Accessed 20 Nov 2021)
500	31.	Bae JP, Lage MJ, Mo D, et al. Obesity and glycemic control in patients with diabetes
501		mellitus: Analysis of physician electronic health records in the US from 2009-2011. J
502		Diabetes Complications 2016;30(2):212–20.
503	32.	Boye KS, Lage MJ, Thieu V, et al. Obesity and glycemic control among people with type 2
504		diabetes in the United States: A retrospective cohort study using insurance claims data. J
505		Diabetes Complications 2021;35(9):107975.
506	33.	Han SJ, Boyko EJ. The evidence for an obesity paradox in type 2 diabetes mellitus.
507		Diabetes Metab J 2018;42(3):179–87.
508	34.	Mobula LM, Stephen F, Carson KA, et al. Translational Metabolic Syndrome Research
509		Predictors of glycemic control in type-2 diabetes mellitus: Evidence from a multicenter
510		study in Ghana. Transl Metab Syndr Res 2018;1:1–8.
511	35.	Schnell O, Crocker JB, Weng J. Impact of HbA1c Testing at Point of Care on Diabetes
512		Management. J Diabetes Sci Technol 2017;11(3):611–7.
513	36.	Ekoru K, Doumatey A, Bentley AR, Chen G, Zhou J, Shriner D, et al. Type 2 diabetes
514		complications and comorbidity in Sub-Saharan Africans. EClinicalMedicine 2019;16:30-
515		41. Available from: https://doi.org/10.1016/j.eclinm.2019.09.001 (Accessed 31 May
516		2022)
517	37.	Fekadu G, Bula K, Bayisa G, Turi E, Tolossa T, Kasaye HK. Challenges And Factors

Associated With Poor Glycemic Control Among Type 2 Diabetes Mellitus Patients At 518 Nekemte Referral Hospital, Western Ethiopia. J Multidiscip Healthc 2019 Nov;12:963-74 519 http://doi.org/10.2147/JMDH.S232691 (Accessed 12 Apr 2021) 520 521 38. Davies MJ, Alessio DAD, Fradkin J, Kernan WN, Mathieu C, Mingrone G. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes 522 Association (ADA) and the European Association for the Study of Diabetes (EASD). 523 524 2018;41:2669-701. 39. Noor SKM, Bushara SOE, Sulaiman AA, Elmadhoun WMY, Ahmed MH. Undiagnosed 525 diabetes mellitus in rural communities in Sudan: prevalence and risk factors. East 526 Mediterr Heal J 2015;21(3):164-70. 527

528